Poland’s Ryvu Bets Big On Blood Cancer Candidate
Data Readouts At ASH
Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.
You may also be interested in...
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.